Black Diamond Therapeutics (BDTX) Net Income (2018 - 2026)

Black Diamond Therapeutics (BDTX) has reported Net Income for 9 consecutive years, with -$11.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income rose 9.49% year-over-year to -$11.1 million; the trailing twelve-month figure through Jun 2026 stood at -$47.6 million (down 734.9% YoY), and the FY2025 full-year result was $16.6 million, up 121.65% from the prior year.
• Net Income eased to -$11.1 million in Q2 2026 per BDTX's latest filing, from -$10.2 million in the prior quarter.
• Across five years, Net Income topped out at $55.1 million in Q1 2025 and bottomed at -$25.3 million in Q1 2022.
• Historically, Net Income has averaged -$14.3 million across 5 years, with a median of -$19.6 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Net Income soared 381.12% in 2025, then slumped 118.57% in 2026.
• Over 5 years, Net Income stood at -$21.2 million in 2022, then climbed by 3.04% to -$20.5 million in 2023, then rose by 13.74% to -$17.7 million in 2024, then gained by 7.25% to -$16.4 million in 2025, then surged by 32.21% to -$11.1 million in 2026.
• According to Business Quant data, Net Income over the past three periods registered -$11.1 million, -$10.2 million, and -$16.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.